Market Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile

MT Newswires Live09-23 16:05

Novo Nordisk (NVO) signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.

Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.

The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.

Novo Nordisk did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2669106133?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669106133","market":"us","top_or_hot":-1,"title":"Market Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile","media":"MT Newswires Live","content":"<html><body><p> Novo Nordisk (NVO) signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.</p><p>Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.</p><p>The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.</p><p>Novo Nordisk did not immediately respond to MT Newswires' request for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Novo Nordisk Mulls Direct NYSE Listing to Boost US Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-23 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Novo Nordisk (NVO) signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.</p><p>Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.</p><p>The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.</p><p>Novo Nordisk did not immediately respond to MT Newswires' request for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"THNR","symbol_name":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669106133","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669106133","pubTimestamp":1790150726,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.Novo Nordisk did not immediately respond to MT Newswires' request for comment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","NVOC":"Corgi NVO 2x Daily ETF","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4007":"制药","NVOX":"2倍做多NVO ETF-Defiance","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4588":"碎股","PPH":"VanEck Pharmaceutical ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","BK4599":"减肥药"},"translate_title":"市场传闻：诺和诺德考虑直接在纽约证券交易所上市以提升美国形象","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOC":0.6,"NVOH":0.6,"NVOX":0.6,"THNR":0.6,"OZEM":0.6,"NVO":1.95,"PPH":0.6},"content_text":"Novo Nordisk (NVO) signaled it may consider upgrading its New York listing as it looks to raise its profile in the US market, the Financial Times reported Wednesday, citing chief executive Mike Doustdar.Doustdar said he sees potential advantages in listing shares directly on the New York Stock Exchange rather than relying on American depositary receipts, though the company is not actively pursuing the move, according to the FT.The US accounts for more than half of Novo's revenue and most of its sales of diabetes and obesity treatments, according to the report.Novo Nordisk did not immediately respond to MT Newswires' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669106133","isCrawlerRequest":true}